The correct treatment of bronchial asthma is a difficult task not only for patients and healthcare professionals but for healthcare authorities as well. The economic burden of the disease is equal to the burden of diabetes mellitus and arterial hypertension. Nearly all indirect costs and not less than a third of direct costs of the treatment of the disease are related to management of exacerbations and poor asthma control. In recent years, there has been a considerable improvement in the treatment of asthma associated with emergence of new medicinal products and delivery devices. Unfortunately, not every patient is able to achieve the optimal disease management level. For this reason, technologies for creation of an effective treatment method for bronchial asthma are undergoing continual improvement nowadays. One of the solutions in this field was the development of inhaler devices producing extrafine aerosol with particle diameter under 2 µm. Such aerosols make it possible for inhalation medicines to reach the small airways, which are the principal site of inflammation in a number of bronchial asthma phenotypes (including bronchial asthma in smokers). The objective of this study was to determine the advantageous medicinal product for bronchial asthma using pharmacoeconomic analysis, on the basis of comparison between costs and effectiveness, safety, and quality of life in treatment with fixed combinations of inhaled glucocorticosteroids and long-acting β2agonists: medicinal products (MP) Foster®, Symbicort® Turbuhaler®, Seretide®, and Seretide® Multidisk. According to the results of the cost-utility analysis, it was determined that the therapy with Foster® is dominant and characterized by the lowest costs with reference to QALY compared to Symbicort® Turbuhaler® and is cost-effective compared to Seretide® and Seretide® Multidisk, on the basis of the obtained values of the incremental cost-utility analysis, which are significantly lower than the willingness-to-pay threshold in the Russian Federation. The budget impact analysis demonstrated that using Foster® for therapy results in budget savings compared to Symbicort® Turbuhaler®, Seretide®, and Seretide® Multidisk when transferring an additional number of patients (21 %) to Foster®.